ADVANTAGE: Merck Does Say “No”
TO THE EDITOR:
As Sox and Rennie point out in their editorial (1), there will always be debate about the true intent of clinical research conducted by a pharmaceutical company in the process of discovering, developing, and commercializing new medicines. Merck agrees that the appropriate approach for investigators, editors, and readers is to consider the scientific importance of the question being asked without regard to the commercial benefits that might accrue depending on the answer.
However, the article by Hill …
This 100-word excerpt has been provided in the absence of an abstract.
Most Read
